[Skip to Content]
[Skip to Content Landing]
Article
October 1960

The Treatment of American (Mucocutaneous) Leishmaniasis with Amphotericin B

Author Affiliations

São Paulo, Brazil

From the Departments of Dermatology and Otolaryngology and Institute of Tropical Medicine, School of Medicine, University of São Paulo.

Arch Dermatol. 1960;82(4):627-635. doi:10.1001/archderm.1960.01580040145026
Abstract

Since amphotericin B was isolated in 1955 by Gold, Stout, Pagano, and Donovick,1 numerous papers have reported its beneficial effect in the treatment of systemic mycoses,2-7 including South American blastomycosis.8-10

American (mucocutaneous) leishmaniasis still constitutes a serious problem in certain areas of Brazil and Latin America, the mucous membrane involvement requiring intensive treatment. On the other hand, there is occurrence of frequent cases of relapses and resistance to the usual therapy. For these reasons the unexpected effectiveness of amphotericin B in the treatment of American leishmaniasis constitutes a new hope for the patients suffering from this disease. The usefulness of the drug in the disease was verified simultaneously by Furtado 11 and Lacaz et al.,12 in four and three patients, respectively. The clinical results were confirmed with in vitro studies by Silva,13 who reported the inhibitory effect of amphotericin B against leptomonas in cultures of Leishmania braziliensis

×